

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل



B 17 Vol

**EVALUATION OF ELEVATED SERUM LIPOPROTEIN (a) AS A
RISK FACTOR FOR LEFT ATRIAL THROMBUS IN PATIENTS
WITH CHRONIC ATRIAL FIBRILLATION**

Thesis

Submitted for the Partial Fulfillment of
The Master Degree of Cardiology

By

SABRY FARAG GABR
MB. B.CH

Supervisors

DR. KHALED EL RABAT

*Assistant Professor of Cardiology
Benha Faculty of Medicine
Zagazig University*

DR. METWALLY EL EMARY

*Lecturer of Cardiology
Benha Faculty of Medicine
Zagazig University*

DR. IBRAHIM MANSOUR

*Lecturer of Cardiology
Benha Faculty of Medicine
Zagazig University*

DR. MOHAMED OSAMA TAHA HUSSIEH

*Fellow of cardiology
National Heart Institute*

*Benha Faculty of Medicine
Zagazig University*

2003

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿ قَالُوا سُبْحَانَكَ

لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا ^ص إِنَّكَ

أَنْتَ الْعَلِيمُ الْحَكِيمُ ﴾

صدق الله العظيم

" البقرة ٣٢ "

ACKNOWLEDGMENT

First and foremost, of thank "Allah" the most kind and merciful.

*I wish to express my sincere thanks and deep gratitude to professor **DR. KHALED EL RABAT**, Assistant Professor of Cardiology Benha faculty of Medicine for his expert guidance throughout this work.*

*I am profoundly grateful to **DR. METWALEY HASSAN EL-EMARY** Lecturer of Cardiology Benha Faculty of Medicine for his kind support and endless help without it this work is not to be a fact.*

*I am also very grateful to **DR. IBRAHIM MANSOUR** Lecturer of Cardiology Benha Faculty of Medicine for his kind support.*

*I am profoundly grateful to **DR. MOHAMED OSAMA TAHA** fellow of cardiology National Heart Institute for his effort in performing this study.*

*I am also very grateful to **DR. AZZA MANSY** consultant Professor of Clinical Pathology National heart Institute for performing the assays of plasminogen, fibrinogen and d-diamers and **DR. RANDA GHANOM** fellow of clinical pathology National Heart Institute for performing the lipid assays.*

At last I would like to express my deep thanks to my seniors and colleagues in National Heart Institute and to my family for their help and support.

Great thanks for every one helped me to finish this work.

Sabry Farag Gabr

CONTENTS

	Page
- Abbreviations.....	
- List of tables.....	
- List of figures.....	
- Introduction.....	1
- Aim of the work.....	3
- Review of literature.....	
Chapter I : Atrial fibrillation	
• Introduction.....	4
• Definitions.....	4
• Classifications.....	5
• Epidemiology and prognosis.....	8
• Pathophysiological mechanisms.....	9
• Associated conditions, clinical manifestations and quality of life.....	15
• Management.	18
- Rhythm control vs heart rate control.....	18
- Grdioevsion.....	18
- Pharmcological cardioversion.....	19
- Electrical ordioversion.....	24
- Maintenance of sinus rhythm.....	26
- Rate control during AF.....	39
- Preventing thromboembolism.....	44
Chapter 2 : Left atrial appendage	
• Introduction.....	54
• Anatomy.....	55
• Comparative anatomy.....	55
• Ultrastructure and anatomical relations.....	56

• Physiology.....	57
• Imaging left atrial appendage thrombus.....	61
• Correlates of left atrial appendage thrombus.....	62
• Obliteration of the left atrial appendage for the prophylaxis of thromboembolism.....	67
• Assessment of left atrial appendage function by transesophageal echocardiography.	72
• Relation between left atrial appendage blood flow velocity, spontaneous echocontrast and thromboembolism.....	74
Chapter (3) : Lipoprotein (a)	
• Structure of Lp(a)	78
• Lp(a) biology.	80
• Metabolism of Lp(a)	81
• Level of Lp(a).....	82
• Functions of Lp(a).....	84
• Cardiovascular pathogenicity of Lp(a).....	85
• Modalities for the treatment of Lp(a) excess.....	87
Chapter 4 : Lipoprotein (a) excess and thrombous formation	
Patient and methods	98
Results	108
Discussion	113
Conclusion	131
Recommendations	137
Limitations of the study	138
Summary	135
References	140
Appendix	142
Arabic summary	

LIST OF ABBREVIATIONS

ACE	: Angiotensin converting enzyme
ACUTE	: Assessment of cardioversion using transesophageal echocardiography
AF	: Atrial fibrillation.
AFFIRM	: Atrial fibrillation follow-up investigation of rhythm management.
ALFA	: Etude en Activite liberate surle fibrillation Auriculaire
ANF	: Atrial natriuretic factor.
Apo (a)	: Apo-protein (a).
ASD	: Atrial septal defect.
AV	: Atrioventricular.
BiD	Twice perday.
bpm	: beat per minute.
CAD	: Coronary artery disease.
CE	: Cholesteryle ester
CHD	: Coronary Heart disease.
CHF	: Congestive heart failure.
DIAMOND- MI	: Danish investigations of arrhythmias and mortility of dofetilide in myocardial infarctions.
DNA	: Deoxyriboneuclic acid
ECG	: Electrocardiogram.
ELISA	: Enzyme-linked Immunosor bent assay.
FA	: Fatty Acids
GI	: gastro-intestinal.
HCM	: Hypertrophic cardiomyopathy.
Hdl	: High density lipoprotein
HF	: Heart failure.

<i>hp</i>	: Hewlett packard.
INR	: International normalized ratio.
IV	: Intravenous.
LA	: Left atrial.
LAA	: Left atrial appendage.
LdL	: Low density lipoprotein
Lp(a)	: Lipoprotein (a).
LV	: Left ventricle.
LVH	: Left ventricular hypertrophy.
MI	: Myocardial infarction.
MR	: Mitral regurge.
MS	: Mitral stenosis.
NA	: Not applicable.
NIDDM	: Non insuline dependant diabetes Melletis
PIAF	: Phamacological intervention in Atrial fibrillation.
PO	: Per mouth.
PPP	: Plasma poor in platelets.
RA	: Right atrium.
RHD	: Rheumatic heart disease.
SD	: Standard deviation.
SEC	: Spontaneous echocontrast.
SFA	: Saturated fatty acids
SPAF	: Stroke prevention in atrial fibrillation.
TEE	: Transesophageal echocardiography.
TG	: Triglyceride
TIA	: Transient ischemic attack.
TPA	: Tissue type plas minogen activator
VF	: Ventricular fibrillation.
Vldl	: Very low density lipoproteins
WPW	: Wolf-parkinson-with syndrome.

LIST OF TABLES

TABLES OF REVIEW		Page
Table (1)	: Vaughan Williams classification of antiarrhythmic drug actions.....	20
Table (2)	: Recommendations for pharmacological cardioversion of AF less than or equal to 7 days duration.....	21
Table (3)	: Recommendations for pharmacological cardioversion of AF more than 7 days duration.	22
Table (4)	: Recommended doses of drugs proven effective for pharmacological cardioversion of atrial fibrillation...	23
Table (5)	: Typical doses of drugs used to maintain sinus rhythm in patients with atrial fibrillation	28
Table (6)	: Types of proarrhythmia during treatment with various antiarrhythmic drugs for atrial fibrillation or atrial flutter according to the vaughan Williams classification	30
Table (7)	: Pharmacological treatment before cardioversion in patients with persistent atrial fibrillation.....	33
Table (8)	: Intravenous pharmacological agents for heart rate control in patients with atrial fibrillation.....	41
Table (9)	: Recommendation for use of orally administered pharmacological agents for heart rate control in patients with atrial fibrillation.....	42
Table (10)	: Risk factors for ischemic stroke and systemic embolism in patients with non valvular atrial fibrillation.....	46
Table (11)	: Published risk-stratifications schemes for primary prevention of thromboembolism in patients with non valvular	48

TABLES OF RESULTS		Page
Table (1)	: Baseline clinical characteristics of patients in the chronic AF (with and without LA thrombus).	114
Table (2)	: Baseline clinical characteristics of patients with chronic AF in high and low LP(a) groups.....	114
Table (3)	: Age and echocardiographic characteristics of patients with chronic AF (with and without thrombus).....	116
Table (4)	: Age and echocardiographic characteristics of patients with chronic AF in high and low Lp(a) groups.....	117
Table (5)	: Prevalence of left atrial thrombus on the basis of Lp(a) concentration among patients under study.	117
Table (6)	: Biochemical characteristics of patients with chronic AF (with and without LA thrombus).....	118
Table (7)	: Biochemical characteristics of patients with chronic AF in high and low Lp(a) groups.....	118
Table (8)	: Correlation between Lp(a) concentration and various parameters under study.....	119

LIST OF FIGURES

FIGURES OF REVIEW		Page
Figure (1)	: Patterns of atrial fibrillation.....	7
Figure (2)	: Hypothetical illustration of cardioversion failure...	32
Figure (3)	: A coronal section of the heart showing trabeculated appendages in contrast to the smooth walled.....	55
Figure (4)	: Picture of a gross specimen of the heart with the pericardium.	55
Figure (5)	: Flow in and out of the appendage during sinus rhythm	58
Figure (6)	: Flow in and out of the appendage thrombi in a patient in atrial fibrillation.	61
Figure (7)	: Prominent trabeculations within the left atrial appendage can easily be misinterpreted as thrombi.	62
Figure (8)	: Left atrial appendage flow during atrial fibrillation, as determined by pulsed Doppler during transoesophageal echocardiography.....	64
FIGURES OF RESULTS		
Figure (1)	: Showing the prevalence of left atrial thrombus on the basis of Lp(a) concentration among patients under study.....	120
Figure (2)	: Showing the age and echocardiographic characteristics of patients with chronic AF (with and without La thrombus).....	121